Clinical Trials

110 enrolled

Phase 1/2 Not yet recruiting

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07604233 2026-05-22

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

30 enrolled

Leukemia, Myeloid

NCT03573700 2026-05-20

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

24 enrolled 9 charts

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05826535 2026-05-20

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

270 enrolled

Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

141 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT07598955 2026-05-20

SELECT-NK-THYM

Thoracic

Thymic epithelial tumor, Thymoma

NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1/2 Terminated

5 enrolled 14 charts

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

18 enrolled

Leukemia, Myeloid, Acute

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07589530 2026-05-15

SOLID-NK

60 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT07589543 2026-05-15

EB-DUALNK-OV

42 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06066359 2026-05-13

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

44 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT06481735 2026-05-08

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05092451 2026-05-06

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

LymphoidMyeloidOther hematologic neoplasmPlasma cell

80 enrolled

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

GastrointestinalGynecologic

51 enrolled

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06930651 2026-05-06

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

42 enrolled

Myeloid Malignancies

NCT07570563 2026-05-06

Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.

24 enrolled

Hematologic Neoplasms

NCT06158828 2026-05-05

ABCD-NK

68 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07509008 2026-05-05

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

10 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT06364423 2026-05-04

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

132 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

320 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05327023 2026-04-28

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

430 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05436418 2026-04-27

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

260 enrolled

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07551349 2026-04-24

DUAL-NK RCC

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07551362 2026-04-24

DUET-GEJ

Stomach Neoplasms

NCT07411599 2026-04-23

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

28 enrolled

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

CNSOther hematologic neoplasm

58 enrolled

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT07523529 2026-04-13

SELECT-2CAR

BreastCNSGastrointestinalGenitourinaryGynecologic

72 enrolled

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02625480 2026-04-09

ZUMA-4

95 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT02830724 2026-04-06

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologic

124 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07510815 2026-04-06

DUAL-MESO-NK

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

45 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT07284433 2026-04-02

QUADvance

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

65 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06961357 2026-03-31

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Dermatologic

Uveal Melanoma, Melanoma

NCT07500220 2026-03-30

DUET-HCC

30 enrolled

Simpson-Golabi-Behmel syndrome, Liver Neoplasms

NCT07502287 2026-03-30

DUAL-NK-NB

CNS

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT05702853 2026-03-27

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07486089 2026-03-20

DUAL-NK-BC

60 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07480928 2026-03-18

DUAL-NK-PDAC

42 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

224 enrolled 15 charts

Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT03214562 2026-03-05

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

116 enrolled

Leukemia, Myeloid, Acute

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

23 enrolled

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

33 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Recurrence

NCT01203722 2026-02-19

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Classical hematologyLymphoidOther hematologic neoplasm

87 enrolled 24 charts

Anemia, Refractory, with Excess of Blasts, Lymphoma, Hematologic Neoplasms

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

DermatologicHead & NeckThoracic

15 enrolled

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK